← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
Cannabis Tinnitus Study
Also known as: Cannabis, Cannabis capsules for tinnitus
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Small Molecule
Stage
Phase 1
Status
Discontinued
Target Gene
—
Route / Mode
Oral
Confidence
71%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
Israel
Population
adult, tinnitus, study-level
Trial IDs
1
Mechanism
Withdrawn hospital-led placebo-controlled study intended to test whether daily cannabis capsules could reduce patient-experienced tinnitus severity.
Indications
Notes
ClinicalTrials.gov verifies a withdrawn Wolfson Medical Center Phase 1 tinnitus study of cannabis capsules versus placebo. The record should not be read as evidence of a current cannabis tinnitus product or company-sponsored pipeline program.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...
IDs: NCT01969474
Key Events
Clinical Trials (1)
Data Checks
institution-led-studyregistry-verified-studydiscontinued-registry-studygeneric-drug-studynot-commercial-pipeline-program
Related Programs
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
AC102 by AudioCure Pharma
Company: AudioCure Pharma · Small Molecule · Phase 2
SPI-1005 by Sound Pharmaceuticals
Company: Sound Pharmaceuticals · Small Molecule · Phase 3
ACOU085 by Acousia Therapeutics
Company: Acousia Therapeutics GmbH · Small Molecule · Phase 2
CIL001 (Paliroden) by Cilcare
Company: Cilcare SAS · Small Molecule · Phase 1/2